PMC:7377212 / 22054-24855 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T53","span":{"begin":1815,"end":1821},"obj":"Body_part"}],"attributes":[{"id":"A53","pred":"fma_id","subj":"T53","obj":"http://purl.org/sig/ont/fma/fma46484"}],"text":"Conflict of interest: D. Armstrong-James reports grants and personal fees from Pulmocide Ltd and Gilead Sciences, outside the submitted work.\nConflict of interest: J. Youngs reports funding from the UK and Ireland Gilead Fellowship Programme.\nConflict of interest: T. Bicanic reports grants and personal fees for lectures from Gilead Sciences Ltd, personal fees for lectures from Pfizer, outside the submitted work.\nConflict of interest: A. Abdolrasouli has received speaker honoraria from Gilead Sciences Ltd, outside the submitted work.\nConflict of interest: D.W. Denning and family hold founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company; D.W. Denning acts or has recently acted as a consultant to Scynexis, Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, and Fujifilm; and has been paid for talks on behalf of Hikma, Gilead, Merck, Mylan and Pfizer; D.W. Denning is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group.\nConflict of interest: E. Johnson has nothing to disclose.\nConflict of interest: V. Mehra reports personal fees for lectures from Pfizer, Novartis, Incyte and Gilead Sciences, grants from MSD, outside the submitted work.\nConflict of interest: T. Pagliuca reports personal fees for advisory board work from Gilead, MSD and Pfizer, outside the submitted work.\nConflict of interest: B. Patel has nothing to disclose.\nConflict of interest: J. Rhodes has nothing to disclose.\nConflict of interest: S. Schelenz reports personal fees for lectures from Gilead Sciences and Pfizer, outside the submitted work.\nConflict of interest: A. Shah reports grant funding from Gilead Sciences and Vertex Pharmaceuticals, and speaker fees from Gilead Sciences and Pfizer.\nConflict of interest: F.L. van de Veerdonk has nothing to disclose.\nConflict of interest: P.E. Verweij has received research grants from Gilead Sciences, F2G Ltd, Pfizer, Thermofisher and Merck, has served on an advisory board for Gilead Sciences, Mundipharma and F2G, and has received speaker honoraria from F2G, Mundipharma, Pfizer and Gilead Sciences.\nConflict of interest: P.L. White reports personal fees from Gilead, Pfizer and F2G, grants from Bruker, outside the submitted work.\nConflict of interest: M.C. Fisher reports grants and personal fees for lectures from Gilead Sciences Ltd, outside the submitted work.\nSupport statement: This work was supported by the Natural Environment Research Council (grant NE/P001165/1), Medical Research Council (grant MR/R015600/1) and Canadian Institute for Advanced Research. Funding information for this article has been deposited with the Crossref Funder Registry."}

LitCovid-PubTator

{"project":"LitCovid-PubTator","denotations":[{"id":"634","span":{"begin":965,"end":983},"obj":"Disease"},{"id":"635","span":{"begin":1086,"end":1119},"obj":"Disease"},{"id":"637","span":{"begin":1163,"end":1170},"obj":"Disease"},{"id":"639","span":{"begin":1916,"end":1931},"obj":"Disease"}],"attributes":[{"id":"A634","pred":"tao:has_database_id","subj":"634","obj":"MESH:D003141"},{"id":"A635","pred":"tao:has_database_id","subj":"635","obj":"MESH:D003141"},{"id":"A637","pred":"tao:has_database_id","subj":"637","obj":"MESH:C535882"},{"id":"A639","pred":"tao:has_database_id","subj":"639","obj":"MESH:C536528"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Conflict of interest: D. Armstrong-James reports grants and personal fees from Pulmocide Ltd and Gilead Sciences, outside the submitted work.\nConflict of interest: J. Youngs reports funding from the UK and Ireland Gilead Fellowship Programme.\nConflict of interest: T. Bicanic reports grants and personal fees for lectures from Gilead Sciences Ltd, personal fees for lectures from Pfizer, outside the submitted work.\nConflict of interest: A. Abdolrasouli has received speaker honoraria from Gilead Sciences Ltd, outside the submitted work.\nConflict of interest: D.W. Denning and family hold founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company; D.W. Denning acts or has recently acted as a consultant to Scynexis, Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, and Fujifilm; and has been paid for talks on behalf of Hikma, Gilead, Merck, Mylan and Pfizer; D.W. Denning is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group.\nConflict of interest: E. Johnson has nothing to disclose.\nConflict of interest: V. Mehra reports personal fees for lectures from Pfizer, Novartis, Incyte and Gilead Sciences, grants from MSD, outside the submitted work.\nConflict of interest: T. Pagliuca reports personal fees for advisory board work from Gilead, MSD and Pfizer, outside the submitted work.\nConflict of interest: B. Patel has nothing to disclose.\nConflict of interest: J. Rhodes has nothing to disclose.\nConflict of interest: S. Schelenz reports personal fees for lectures from Gilead Sciences and Pfizer, outside the submitted work.\nConflict of interest: A. Shah reports grant funding from Gilead Sciences and Vertex Pharmaceuticals, and speaker fees from Gilead Sciences and Pfizer.\nConflict of interest: F.L. van de Veerdonk has nothing to disclose.\nConflict of interest: P.E. Verweij has received research grants from Gilead Sciences, F2G Ltd, Pfizer, Thermofisher and Merck, has served on an advisory board for Gilead Sciences, Mundipharma and F2G, and has received speaker honoraria from F2G, Mundipharma, Pfizer and Gilead Sciences.\nConflict of interest: P.L. White reports personal fees from Gilead, Pfizer and F2G, grants from Bruker, outside the submitted work.\nConflict of interest: M.C. Fisher reports grants and personal fees for lectures from Gilead Sciences Ltd, outside the submitted work.\nSupport statement: This work was supported by the Natural Environment Research Council (grant NE/P001165/1), Medical Research Council (grant MR/R015600/1) and Canadian Institute for Advanced Research. Funding information for this article has been deposited with the Crossref Funder Registry."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T226","span":{"begin":965,"end":975},"obj":"Disease"},{"id":"T227","span":{"begin":1003,"end":1016},"obj":"Disease"},{"id":"T228","span":{"begin":1086,"end":1096},"obj":"Disease"},{"id":"T229","span":{"begin":1106,"end":1119},"obj":"Disease"},{"id":"T230","span":{"begin":1325,"end":1328},"obj":"Disease"},{"id":"T231","span":{"begin":1451,"end":1454},"obj":"Disease"}],"attributes":[{"id":"A226","pred":"mondo_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A227","pred":"mondo_id","subj":"T227","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A228","pred":"mondo_id","subj":"T228","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A229","pred":"mondo_id","subj":"T229","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A230","pred":"mondo_id","subj":"T230","obj":"http://purl.obolibrary.org/obo/MONDO_0010088"},{"id":"A231","pred":"mondo_id","subj":"T231","obj":"http://purl.obolibrary.org/obo/MONDO_0010088"}],"text":"Conflict of interest: D. Armstrong-James reports grants and personal fees from Pulmocide Ltd and Gilead Sciences, outside the submitted work.\nConflict of interest: J. Youngs reports funding from the UK and Ireland Gilead Fellowship Programme.\nConflict of interest: T. Bicanic reports grants and personal fees for lectures from Gilead Sciences Ltd, personal fees for lectures from Pfizer, outside the submitted work.\nConflict of interest: A. Abdolrasouli has received speaker honoraria from Gilead Sciences Ltd, outside the submitted work.\nConflict of interest: D.W. Denning and family hold founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company; D.W. Denning acts or has recently acted as a consultant to Scynexis, Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, and Fujifilm; and has been paid for talks on behalf of Hikma, Gilead, Merck, Mylan and Pfizer; D.W. Denning is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group.\nConflict of interest: E. Johnson has nothing to disclose.\nConflict of interest: V. Mehra reports personal fees for lectures from Pfizer, Novartis, Incyte and Gilead Sciences, grants from MSD, outside the submitted work.\nConflict of interest: T. Pagliuca reports personal fees for advisory board work from Gilead, MSD and Pfizer, outside the submitted work.\nConflict of interest: B. Patel has nothing to disclose.\nConflict of interest: J. Rhodes has nothing to disclose.\nConflict of interest: S. Schelenz reports personal fees for lectures from Gilead Sciences and Pfizer, outside the submitted work.\nConflict of interest: A. Shah reports grant funding from Gilead Sciences and Vertex Pharmaceuticals, and speaker fees from Gilead Sciences and Pfizer.\nConflict of interest: F.L. van de Veerdonk has nothing to disclose.\nConflict of interest: P.E. Verweij has received research grants from Gilead Sciences, F2G Ltd, Pfizer, Thermofisher and Merck, has served on an advisory board for Gilead Sciences, Mundipharma and F2G, and has received speaker honoraria from F2G, Mundipharma, Pfizer and Gilead Sciences.\nConflict of interest: P.L. White reports personal fees from Gilead, Pfizer and F2G, grants from Bruker, outside the submitted work.\nConflict of interest: M.C. Fisher reports grants and personal fees for lectures from Gilead Sciences Ltd, outside the submitted work.\nSupport statement: This work was supported by the Natural Environment Research Council (grant NE/P001165/1), Medical Research Council (grant MR/R015600/1) and Canadian Institute for Advanced Research. Funding information for this article has been deposited with the Crossref Funder Registry."}

LitCovid-PD-CLO

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T306","span":{"begin":653,"end":663},"obj":"Chemical"},{"id":"T307","span":{"begin":1028,"end":1033},"obj":"Chemical"},{"id":"T308","span":{"begin":1131,"end":1136},"obj":"Chemical"},{"id":"T309","span":{"begin":2604,"end":2606},"obj":"Chemical"},{"id":"T310","span":{"begin":2651,"end":2653},"obj":"Chemical"}],"attributes":[{"id":"A306","pred":"chebi_id","subj":"T306","obj":"http://purl.obolibrary.org/obo/CHEBI_35718"},{"id":"A307","pred":"chebi_id","subj":"T307","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A308","pred":"chebi_id","subj":"T308","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A309","pred":"chebi_id","subj":"T309","obj":"http://purl.obolibrary.org/obo/CHEBI_73824"},{"id":"A310","pred":"chebi_id","subj":"T310","obj":"http://purl.obolibrary.org/obo/CHEBI_74698"}],"text":"Conflict of interest: D. Armstrong-James reports grants and personal fees from Pulmocide Ltd and Gilead Sciences, outside the submitted work.\nConflict of interest: J. Youngs reports funding from the UK and Ireland Gilead Fellowship Programme.\nConflict of interest: T. Bicanic reports grants and personal fees for lectures from Gilead Sciences Ltd, personal fees for lectures from Pfizer, outside the submitted work.\nConflict of interest: A. Abdolrasouli has received speaker honoraria from Gilead Sciences Ltd, outside the submitted work.\nConflict of interest: D.W. Denning and family hold founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company; D.W. Denning acts or has recently acted as a consultant to Scynexis, Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, and Fujifilm; and has been paid for talks on behalf of Hikma, Gilead, Merck, Mylan and Pfizer; D.W. Denning is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group.\nConflict of interest: E. Johnson has nothing to disclose.\nConflict of interest: V. Mehra reports personal fees for lectures from Pfizer, Novartis, Incyte and Gilead Sciences, grants from MSD, outside the submitted work.\nConflict of interest: T. Pagliuca reports personal fees for advisory board work from Gilead, MSD and Pfizer, outside the submitted work.\nConflict of interest: B. Patel has nothing to disclose.\nConflict of interest: J. Rhodes has nothing to disclose.\nConflict of interest: S. Schelenz reports personal fees for lectures from Gilead Sciences and Pfizer, outside the submitted work.\nConflict of interest: A. Shah reports grant funding from Gilead Sciences and Vertex Pharmaceuticals, and speaker fees from Gilead Sciences and Pfizer.\nConflict of interest: F.L. van de Veerdonk has nothing to disclose.\nConflict of interest: P.E. Verweij has received research grants from Gilead Sciences, F2G Ltd, Pfizer, Thermofisher and Merck, has served on an advisory board for Gilead Sciences, Mundipharma and F2G, and has received speaker honoraria from F2G, Mundipharma, Pfizer and Gilead Sciences.\nConflict of interest: P.L. White reports personal fees from Gilead, Pfizer and F2G, grants from Bruker, outside the submitted work.\nConflict of interest: M.C. Fisher reports grants and personal fees for lectures from Gilead Sciences Ltd, outside the submitted work.\nSupport statement: This work was supported by the Natural Environment Research Council (grant NE/P001165/1), Medical Research Council (grant MR/R015600/1) and Canadian Institute for Advanced Research. Funding information for this article has been deposited with the Crossref Funder Registry."}

LitCovid-sentences